Not only are the environment/lifestyle/economic circumstances underlying overweight/obesity often unchanged during the GLP-1 receptor agonist treatment period, but, in addition, weight loss upregulates appetite hormones. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.